Literature DB >> 18843588

Periventricular leukomalacia in premature infants in mainland China.

Jing Liu1, Jian Li, Gui-Lian Qin, Yan-Hua Chen, Qi Wang.   

Abstract

Periventricular leukomalacia (PVL) in premature infants is a major cause of mortality and disability. However, while China is the largest developing country, there is an absence of data concerning PVL. This study was carried out in order to explore the incidence rate and analyze the high-risk factors of PVL in premature infants, and to suggest a working protocol for the prevention of PVL in newborns at risk. The cohort prospective study included 921 premature infants < 37 weeks' gestation from January 2004 to July 2007. The study group was comprised of 271 premature infants with an ultrasound diagnosis of PVL and the control group was comprised of 650 premature infants who were submitted to the same evaluation protocol but did not show any echographic signs of PVL. The results showed that the incidence rate of PVL was 29.4% in China. High-degree PVL accounted for < 12% and > 88% of PVL was low-degree. The incidence rate was much higher when premature infants were accompanied by the following complications: low gestational age, low birth weight, prolonged rupture of membranes, chorionitis, mechanical ventilation, periventricular-ventricular hemorrhage, hypocapnia, and hyperlactacidemia. Severe complications that occur in premature infants also significantly increase the incidence of PVL. Antenatal corticosteroids can significantly decrease the incidence rate of PVL. This investigation provided a theoretical reference for the prevention of premature PVL.

Entities:  

Mesh:

Year:  2008        PMID: 18843588     DOI: 10.1055/s-0028-1083841

Source DB:  PubMed          Journal:  Am J Perinatol        ISSN: 0735-1631            Impact factor:   1.862


  8 in total

Review 1.  Pathophysiology of glia in perinatal white matter injury.

Authors:  Stephen A Back; Paul A Rosenberg
Journal:  Glia       Date:  2014-03-31       Impact factor: 7.452

Review 2.  White matter injury in the preterm infant: pathology and mechanisms.

Authors:  Stephen A Back
Journal:  Acta Neuropathol       Date:  2017-05-22       Impact factor: 17.088

Review 3.  The instrumented fetal sheep as a model of cerebral white matter injury in the premature infant.

Authors:  Stephen A Back; Art Riddle; Justin Dean; A Roger Hohimer
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

4.  The whole spectrum of cystic periventricular leukomalacia of the preterm infant: results from a large consecutive case series.

Authors:  Bernhard Resch; Elisabeth Resch; Ute Maurer-Fellbaum; Elisabeth Pichler-Stachl; Michael Riccabona; Nora Hofer; Berndt Urlesberger
Journal:  Childs Nerv Syst       Date:  2015-06-23       Impact factor: 1.475

Review 5.  Cerebral white and gray matter injury in newborns: new insights into pathophysiology and management.

Authors:  Stephen A Back
Journal:  Clin Perinatol       Date:  2014-03       Impact factor: 3.430

Review 6.  Recent Investigations on Neurotransmitters' Role in Acute White Matter Injury of Perinatal Glia and Pharmacotherapies-Glia Dynamics in Stem Cell Therapy.

Authors:  Narasimha M Beeraka; P R Hemanth Vikram; M V Greeshma; Chinnappa A Uthaiah; Tahani Huria; Junqi Liu; Pramod Kumar; Vladimir N Nikolenko; Kirill V Bulygin; Mikhail Y Sinelnikov; Olga Sukocheva; Ruitai Fan
Journal:  Mol Neurobiol       Date:  2022-01-18       Impact factor: 5.590

Review 7.  Survival, morbidity, growth and developmental delay for babies born preterm in low and middle income countries - a systematic review of outcomes measured.

Authors:  Melissa Gladstone; Clare Oliver; Nynke Van den Broek
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

Review 8.  Carbon dioxide levels in neonates: what are safe parameters?

Authors:  Sie Kei Wong; M Chim; J Allen; A Butler; J Tyrrell; T Hurley; M McGovern; M Omer; N Lagan; J Meehan; E P Cummins; E J Molloy
Journal:  Pediatr Res       Date:  2021-07-06       Impact factor: 3.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.